Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 1-Year High – Here’s Why

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)’s share price reached a new 52-week high during trading on Thursday . The company traded as high as $16.61 and last traded at $16.1010, with a volume of 228484 shares. The stock had previously closed at $16.28.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on AMRX shares. UBS Group started coverage on shares of Amneal Pharmaceuticals in a research note on Friday, April 17th. They issued a “buy” rating and a $19.00 price objective for the company. Weiss Ratings lowered shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. Barclays raised their price objective on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Zacks Research downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Finally, Wall Street Zen downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 13th. Five investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Amneal Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $15.80.

Amneal Pharmaceuticals Trading Down 1.2%

The firm has a market cap of $5.13 billion, a P/E ratio of 42.32 and a beta of 1.30. The business’s fifty day moving average price is $13.26 and its two-hundred day moving average price is $13.18.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. The business had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. Research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current fiscal year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, Director Deborah M. Autor sold 34,819 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the transaction, the director owned 93,660 shares in the company, valued at approximately $1,211,960.40. This trade represents a 27.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 17.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Spire Wealth Management raised its holdings in Amneal Pharmaceuticals by 66.6% in the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after acquiring an additional 1,023 shares during the period. Intech Investment Management LLC raised its holdings in Amneal Pharmaceuticals by 1.2% in the 4th quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock worth $1,229,000 after acquiring an additional 1,159 shares during the period. Hsbc Holdings PLC raised its holdings in Amneal Pharmaceuticals by 1.6% in the 4th quarter. Hsbc Holdings PLC now owns 101,945 shares of the company’s stock worth $1,297,000 after acquiring an additional 1,569 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Amneal Pharmaceuticals by 2.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock worth $859,000 after acquiring an additional 1,582 shares during the period. Finally, Comerica Bank raised its holdings in Amneal Pharmaceuticals by 56.1% in the 4th quarter. Comerica Bank now owns 4,690 shares of the company’s stock worth $59,000 after acquiring an additional 1,685 shares during the period. Institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.